Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15966860 | 0.90 | ALDH1A1 (0.82) | ALDH1A1KDM4ESMN1; SMN2GSK3BHSD17B10 | |
| SCHEMBL5529505 | 0.90 | ALDH1A1 (0.81) | ALDH1A1KDM4ESMN1; SMN2GSK3BHSD17B10 | |
| SCHEMBL11068656 | 0.86 | ALDH1A1 (0.76) | ALDH1A1KDM4ESMN1; SMN2HSD17B10LMNA | |
| SCHEMBL5530559 | 0.86 | ALDH1A1 (0.76) | ALDH1A1KDM4ESMN1; SMN2GSK3BHSD17B10 | |
| SCHEMBL28677828 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KDM4EGSK3BHSD17B10HPGD | |
| SCHEMBL5531289 | 0.86 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD | |
| SCHEMBL10805347 | 0.85 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD | |
| SCHEMBL15966796 | 0.85 | ALDH1A1 (0.83) | ALDH1A1KDM4ESMN1; SMN2GSK3BHSD17B10 | |
| SCHEMBL6087197 | 0.85 | ALDH1A1 (0.73) | ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD | |
| SCHEMBL10805754 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ESMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757369-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-09-12 | — | — | US | disclosed |
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-07-13 | — | — | US | disclosed |
| EP-2769720-B1 | HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS | CONSEJO SUPERIOR DE INVESTIG CIENTÍFICAS (CSIC) (ES) | 2017-03-29 | — | — | EP | disclosed |
| US-9585879-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2017-03-07 | — | — | US | disclosed |
| US-20160113918-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2016-04-28 | — | — | US | disclosed |
| US-9193688-B2 | Heterocyclic GSK-3 allosteric modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-11-24 | — | — | US | disclosed |
| US-20150057311-A1 | Heterocyclic GSK-3 Allosteric Modulators | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2015-02-26 | — | — | US | disclosed |
| EP-2769720-A1 | HETEROCYCLIC GSK-3 ALLOSTERIC MODULATORS | Consejo Superior De Investigaciones Científicas (CSIC) (ES) | 2014-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196850-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | ALDH1A1 3820/4885KDM4E 878/4885SMN1; SMN2 1444/4885 |
| US-20160113918-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | ALDH1A1 3820/4885KDM4E 878/4885SMN1; SMN2 1444/4885 |
| US-20150057311-A1 | Heterocyclic GSK-3 Allosteric Modulators | GSK3B, GSK3A, GSKIP | ALDH1A1 3820/4885KDM4E 878/4885SMN1; SMN2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.